nodes	percent_of_prediction	percent_of_DWPC	metapath
Pergolide—HTR2B—Sorafenib—liver cancer	0.234	0.462	CbGbCtD
Pergolide—HTR2C—Sorafenib—liver cancer	0.153	0.301	CbGbCtD
Pergolide—CYP2D6—Sorafenib—liver cancer	0.0457	0.0902	CbGbCtD
Pergolide—CYP3A4—Sorafenib—liver cancer	0.0291	0.0573	CbGbCtD
Pergolide—CYP2D6—Doxorubicin—liver cancer	0.0277	0.0547	CbGbCtD
Pergolide—CYP3A4—Doxorubicin—liver cancer	0.0176	0.0348	CbGbCtD
Pergolide—Dyspepsia—Sorafenib—liver cancer	0.000702	0.0018	CcSEcCtD
Pergolide—Oesophagitis—Doxorubicin—liver cancer	0.000698	0.00179	CcSEcCtD
Pergolide—Coma—Doxorubicin—liver cancer	0.000698	0.00179	CcSEcCtD
Pergolide—Decreased appetite—Sorafenib—liver cancer	0.000693	0.00177	CcSEcCtD
Pergolide—Thrombophlebitis—Epirubicin—liver cancer	0.000693	0.00177	CcSEcCtD
Pergolide—Bladder pain—Doxorubicin—liver cancer	0.000691	0.00177	CcSEcCtD
Pergolide—Neoplasm—Doxorubicin—liver cancer	0.000691	0.00177	CcSEcCtD
Pergolide—Diabetes mellitus—Epirubicin—liver cancer	0.000689	0.00176	CcSEcCtD
Pergolide—Pain—Sorafenib—liver cancer	0.000682	0.00174	CcSEcCtD
Pergolide—Constipation—Sorafenib—liver cancer	0.000682	0.00174	CcSEcCtD
Pergolide—Pulmonary oedema—Doxorubicin—liver cancer	0.00068	0.00174	CcSEcCtD
Pergolide—Vascular purpura—Epirubicin—liver cancer	0.00067	0.00171	CcSEcCtD
Pergolide—Hypertonia—Doxorubicin—liver cancer	0.00067	0.00171	CcSEcCtD
Pergolide—Eczema—Epirubicin—liver cancer	0.000667	0.00171	CcSEcCtD
Pergolide—Abnormal vision—Doxorubicin—liver cancer	0.000667	0.00171	CcSEcCtD
Pergolide—Eye pain—Epirubicin—liver cancer	0.000664	0.0017	CcSEcCtD
Pergolide—Sepsis—Doxorubicin—liver cancer	0.000663	0.0017	CcSEcCtD
Pergolide—Mental disability—Doxorubicin—liver cancer	0.000663	0.0017	CcSEcCtD
Pergolide—Cardiac failure congestive—Epirubicin—liver cancer	0.000661	0.00169	CcSEcCtD
Pergolide—Gastrointestinal pain—Sorafenib—liver cancer	0.000652	0.00167	CcSEcCtD
Pergolide—Lymphadenopathy—Doxorubicin—liver cancer	0.00065	0.00166	CcSEcCtD
Pergolide—Thrombophlebitis—Doxorubicin—liver cancer	0.000641	0.00164	CcSEcCtD
Pergolide—Increased appetite—Epirubicin—liver cancer	0.000638	0.00163	CcSEcCtD
Pergolide—Diabetes mellitus—Doxorubicin—liver cancer	0.000638	0.00163	CcSEcCtD
Pergolide—Abdominal pain—Sorafenib—liver cancer	0.00063	0.00161	CcSEcCtD
Pergolide—Body temperature increased—Sorafenib—liver cancer	0.00063	0.00161	CcSEcCtD
Pergolide—Dermatitis bullous—Epirubicin—liver cancer	0.000627	0.0016	CcSEcCtD
Pergolide—Purpura—Epirubicin—liver cancer	0.000622	0.00159	CcSEcCtD
Pergolide—Vascular purpura—Doxorubicin—liver cancer	0.00062	0.00159	CcSEcCtD
Pergolide—Eczema—Doxorubicin—liver cancer	0.000617	0.00158	CcSEcCtD
Pergolide—Eye pain—Doxorubicin—liver cancer	0.000615	0.00157	CcSEcCtD
Pergolide—Hypoglycaemia—Epirubicin—liver cancer	0.000614	0.00157	CcSEcCtD
Pergolide—Cerebrovascular accident—Epirubicin—liver cancer	0.000612	0.00157	CcSEcCtD
Pergolide—Cardiac failure congestive—Doxorubicin—liver cancer	0.000612	0.00156	CcSEcCtD
Pergolide—Diplopia—Epirubicin—liver cancer	0.0006	0.00153	CcSEcCtD
Pergolide—Increased appetite—Doxorubicin—liver cancer	0.000591	0.00151	CcSEcCtD
Pergolide—Migraine—Epirubicin—liver cancer	0.00059	0.00151	CcSEcCtD
Pergolide—Affect lability—Epirubicin—liver cancer	0.00059	0.00151	CcSEcCtD
Pergolide—Dermatitis bullous—Doxorubicin—liver cancer	0.000581	0.00148	CcSEcCtD
Pergolide—Face oedema—Epirubicin—liver cancer	0.000579	0.00148	CcSEcCtD
Pergolide—Purpura—Doxorubicin—liver cancer	0.000576	0.00147	CcSEcCtD
Pergolide—Asthenia—Sorafenib—liver cancer	0.000572	0.00146	CcSEcCtD
Pergolide—Cardiac arrest—Epirubicin—liver cancer	0.00057	0.00146	CcSEcCtD
Pergolide—Hypoglycaemia—Doxorubicin—liver cancer	0.000569	0.00145	CcSEcCtD
Pergolide—Mood swings—Epirubicin—liver cancer	0.000568	0.00145	CcSEcCtD
Pergolide—Cerebrovascular accident—Doxorubicin—liver cancer	0.000566	0.00145	CcSEcCtD
Pergolide—Pruritus—Sorafenib—liver cancer	0.000564	0.00144	CcSEcCtD
Pergolide—Ataxia—Epirubicin—liver cancer	0.000564	0.00144	CcSEcCtD
Pergolide—Dehydration—Epirubicin—liver cancer	0.000558	0.00143	CcSEcCtD
Pergolide—Diplopia—Doxorubicin—liver cancer	0.000555	0.00142	CcSEcCtD
Pergolide—Liver function test abnormal—Epirubicin—liver cancer	0.000554	0.00142	CcSEcCtD
Pergolide—Dry skin—Epirubicin—liver cancer	0.00055	0.00141	CcSEcCtD
Pergolide—Orthostatic hypotension—Epirubicin—liver cancer	0.000548	0.0014	CcSEcCtD
Pergolide—Migraine—Doxorubicin—liver cancer	0.000546	0.0014	CcSEcCtD
Pergolide—Affect lability—Doxorubicin—liver cancer	0.000546	0.0014	CcSEcCtD
Pergolide—Hypokalaemia—Epirubicin—liver cancer	0.000546	0.0014	CcSEcCtD
Pergolide—Diarrhoea—Sorafenib—liver cancer	0.000546	0.0014	CcSEcCtD
Pergolide—Face oedema—Doxorubicin—liver cancer	0.000536	0.00137	CcSEcCtD
Pergolide—Gastritis—Epirubicin—liver cancer	0.000531	0.00136	CcSEcCtD
Pergolide—Cardiac arrest—Doxorubicin—liver cancer	0.000528	0.00135	CcSEcCtD
Pergolide—Dizziness—Sorafenib—liver cancer	0.000527	0.00135	CcSEcCtD
Pergolide—Mood swings—Doxorubicin—liver cancer	0.000526	0.00134	CcSEcCtD
Pergolide—Abdominal distension—Epirubicin—liver cancer	0.000522	0.00133	CcSEcCtD
Pergolide—Ataxia—Doxorubicin—liver cancer	0.000522	0.00133	CcSEcCtD
Pergolide—Influenza—Epirubicin—liver cancer	0.000518	0.00133	CcSEcCtD
Pergolide—Asthma—Epirubicin—liver cancer	0.000518	0.00133	CcSEcCtD
Pergolide—Dysphagia—Epirubicin—liver cancer	0.000518	0.00133	CcSEcCtD
Pergolide—Dehydration—Doxorubicin—liver cancer	0.000516	0.00132	CcSEcCtD
Pergolide—Eosinophilia—Epirubicin—liver cancer	0.000513	0.00131	CcSEcCtD
Pergolide—Liver function test abnormal—Doxorubicin—liver cancer	0.000512	0.00131	CcSEcCtD
Pergolide—Dry skin—Doxorubicin—liver cancer	0.000509	0.0013	CcSEcCtD
Pergolide—Pancreatitis—Epirubicin—liver cancer	0.000508	0.0013	CcSEcCtD
Pergolide—Vomiting—Sorafenib—liver cancer	0.000507	0.0013	CcSEcCtD
Pergolide—Orthostatic hypotension—Doxorubicin—liver cancer	0.000507	0.0013	CcSEcCtD
Pergolide—Hypokalaemia—Doxorubicin—liver cancer	0.000505	0.00129	CcSEcCtD
Pergolide—Angina pectoris—Epirubicin—liver cancer	0.000505	0.00129	CcSEcCtD
Pergolide—Rash—Sorafenib—liver cancer	0.000503	0.00129	CcSEcCtD
Pergolide—Dermatitis—Sorafenib—liver cancer	0.000502	0.00128	CcSEcCtD
Pergolide—Headache—Sorafenib—liver cancer	0.0005	0.00128	CcSEcCtD
Pergolide—Bronchitis—Epirubicin—liver cancer	0.000498	0.00127	CcSEcCtD
Pergolide—Gastritis—Doxorubicin—liver cancer	0.000491	0.00126	CcSEcCtD
Pergolide—Dysuria—Epirubicin—liver cancer	0.000485	0.00124	CcSEcCtD
Pergolide—Abdominal distension—Doxorubicin—liver cancer	0.000483	0.00123	CcSEcCtD
Pergolide—Asthma—Doxorubicin—liver cancer	0.00048	0.00123	CcSEcCtD
Pergolide—Dysphagia—Doxorubicin—liver cancer	0.00048	0.00123	CcSEcCtD
Pergolide—Influenza—Doxorubicin—liver cancer	0.00048	0.00123	CcSEcCtD
Pergolide—Pollakiuria—Epirubicin—liver cancer	0.000479	0.00122	CcSEcCtD
Pergolide—Eosinophilia—Doxorubicin—liver cancer	0.000475	0.00121	CcSEcCtD
Pergolide—Nausea—Sorafenib—liver cancer	0.000474	0.00121	CcSEcCtD
Pergolide—Weight increased—Epirubicin—liver cancer	0.000472	0.00121	CcSEcCtD
Pergolide—Pancreatitis—Doxorubicin—liver cancer	0.00047	0.0012	CcSEcCtD
Pergolide—Weight decreased—Epirubicin—liver cancer	0.000469	0.0012	CcSEcCtD
Pergolide—Hyperglycaemia—Epirubicin—liver cancer	0.000468	0.0012	CcSEcCtD
Pergolide—Angina pectoris—Doxorubicin—liver cancer	0.000467	0.00119	CcSEcCtD
Pergolide—Pneumonia—Epirubicin—liver cancer	0.000465	0.00119	CcSEcCtD
Pergolide—Bronchitis—Doxorubicin—liver cancer	0.000461	0.00118	CcSEcCtD
Pergolide—Renal failure—Epirubicin—liver cancer	0.000454	0.00116	CcSEcCtD
Pergolide—Neuropathy peripheral—Epirubicin—liver cancer	0.000453	0.00116	CcSEcCtD
Pergolide—Jaundice—Epirubicin—liver cancer	0.00045	0.00115	CcSEcCtD
Pergolide—Conjunctivitis—Epirubicin—liver cancer	0.000449	0.00115	CcSEcCtD
Pergolide—Urinary tract infection—Epirubicin—liver cancer	0.000449	0.00115	CcSEcCtD
Pergolide—Dysuria—Doxorubicin—liver cancer	0.000448	0.00115	CcSEcCtD
Pergolide—Sweating—Epirubicin—liver cancer	0.000443	0.00113	CcSEcCtD
Pergolide—Pollakiuria—Doxorubicin—liver cancer	0.000443	0.00113	CcSEcCtD
Pergolide—Haematuria—Epirubicin—liver cancer	0.000441	0.00113	CcSEcCtD
Pergolide—Weight increased—Doxorubicin—liver cancer	0.000436	0.00112	CcSEcCtD
Pergolide—Epistaxis—Epirubicin—liver cancer	0.000436	0.00111	CcSEcCtD
Pergolide—Weight decreased—Doxorubicin—liver cancer	0.000434	0.00111	CcSEcCtD
Pergolide—Sinusitis—Epirubicin—liver cancer	0.000434	0.00111	CcSEcCtD
Pergolide—Hyperglycaemia—Doxorubicin—liver cancer	0.000433	0.00111	CcSEcCtD
Pergolide—Pneumonia—Doxorubicin—liver cancer	0.00043	0.0011	CcSEcCtD
Pergolide—Bradycardia—Epirubicin—liver cancer	0.000422	0.00108	CcSEcCtD
Pergolide—Renal failure—Doxorubicin—liver cancer	0.00042	0.00108	CcSEcCtD
Pergolide—Neuropathy peripheral—Doxorubicin—liver cancer	0.000419	0.00107	CcSEcCtD
Pergolide—Jaundice—Doxorubicin—liver cancer	0.000417	0.00107	CcSEcCtD
Pergolide—Rhinitis—Epirubicin—liver cancer	0.000416	0.00106	CcSEcCtD
Pergolide—Conjunctivitis—Doxorubicin—liver cancer	0.000416	0.00106	CcSEcCtD
Pergolide—Urinary tract infection—Doxorubicin—liver cancer	0.000416	0.00106	CcSEcCtD
Pergolide—Hepatitis—Epirubicin—liver cancer	0.000415	0.00106	CcSEcCtD
Pergolide—Pharyngitis—Epirubicin—liver cancer	0.000412	0.00105	CcSEcCtD
Pergolide—Sweating—Doxorubicin—liver cancer	0.00041	0.00105	CcSEcCtD
Pergolide—Oedema peripheral—Epirubicin—liver cancer	0.000409	0.00105	CcSEcCtD
Pergolide—Haematuria—Doxorubicin—liver cancer	0.000408	0.00104	CcSEcCtD
Pergolide—Epistaxis—Doxorubicin—liver cancer	0.000403	0.00103	CcSEcCtD
Pergolide—Sinusitis—Doxorubicin—liver cancer	0.000401	0.00103	CcSEcCtD
Pergolide—Visual impairment—Epirubicin—liver cancer	0.0004	0.00102	CcSEcCtD
Pergolide—Bradycardia—Doxorubicin—liver cancer	0.000391	0.001	CcSEcCtD
Pergolide—Eye disorder—Epirubicin—liver cancer	0.000388	0.000992	CcSEcCtD
Pergolide—Tinnitus—Epirubicin—liver cancer	0.000387	0.000989	CcSEcCtD
Pergolide—Rhinitis—Doxorubicin—liver cancer	0.000385	0.000984	CcSEcCtD
Pergolide—Hepatitis—Doxorubicin—liver cancer	0.000384	0.000982	CcSEcCtD
Pergolide—Pharyngitis—Doxorubicin—liver cancer	0.000381	0.000974	CcSEcCtD
Pergolide—Oedema peripheral—Doxorubicin—liver cancer	0.000378	0.000967	CcSEcCtD
Pergolide—Chills—Epirubicin—liver cancer	0.000372	0.000952	CcSEcCtD
Pergolide—Arrhythmia—Epirubicin—liver cancer	0.000371	0.000948	CcSEcCtD
Pergolide—Visual impairment—Doxorubicin—liver cancer	0.00037	0.000946	CcSEcCtD
Pergolide—Alopecia—Epirubicin—liver cancer	0.000367	0.000938	CcSEcCtD
Pergolide—Eye disorder—Doxorubicin—liver cancer	0.000359	0.000918	CcSEcCtD
Pergolide—Tinnitus—Doxorubicin—liver cancer	0.000358	0.000915	CcSEcCtD
Pergolide—Flatulence—Epirubicin—liver cancer	0.000356	0.00091	CcSEcCtD
Pergolide—Tension—Epirubicin—liver cancer	0.000354	0.000906	CcSEcCtD
Pergolide—Dysgeusia—Epirubicin—liver cancer	0.000354	0.000905	CcSEcCtD
Pergolide—Nervousness—Epirubicin—liver cancer	0.000351	0.000897	CcSEcCtD
Pergolide—Back pain—Epirubicin—liver cancer	0.000349	0.000893	CcSEcCtD
Pergolide—Chills—Doxorubicin—liver cancer	0.000344	0.000881	CcSEcCtD
Pergolide—Arrhythmia—Doxorubicin—liver cancer	0.000343	0.000877	CcSEcCtD
Pergolide—Alopecia—Doxorubicin—liver cancer	0.000339	0.000868	CcSEcCtD
Pergolide—Ill-defined disorder—Epirubicin—liver cancer	0.000335	0.000857	CcSEcCtD
Pergolide—Anaemia—Epirubicin—liver cancer	0.000334	0.000854	CcSEcCtD
Pergolide—Agitation—Epirubicin—liver cancer	0.000332	0.000849	CcSEcCtD
Pergolide—Flatulence—Doxorubicin—liver cancer	0.000329	0.000842	CcSEcCtD
Pergolide—Tension—Doxorubicin—liver cancer	0.000328	0.000839	CcSEcCtD
Pergolide—Dysgeusia—Doxorubicin—liver cancer	0.000327	0.000837	CcSEcCtD
Pergolide—Malaise—Epirubicin—liver cancer	0.000326	0.000833	CcSEcCtD
Pergolide—Nervousness—Doxorubicin—liver cancer	0.000325	0.00083	CcSEcCtD
Pergolide—Vertigo—Epirubicin—liver cancer	0.000324	0.00083	CcSEcCtD
Pergolide—Syncope—Epirubicin—liver cancer	0.000324	0.000828	CcSEcCtD
Pergolide—Leukopenia—Epirubicin—liver cancer	0.000323	0.000827	CcSEcCtD
Pergolide—Back pain—Doxorubicin—liver cancer	0.000323	0.000827	CcSEcCtD
Pergolide—Palpitations—Epirubicin—liver cancer	0.000319	0.000816	CcSEcCtD
Pergolide—Loss of consciousness—Epirubicin—liver cancer	0.000317	0.000812	CcSEcCtD
Pergolide—Cough—Epirubicin—liver cancer	0.000315	0.000806	CcSEcCtD
Pergolide—Convulsion—Epirubicin—liver cancer	0.000313	0.0008	CcSEcCtD
Pergolide—Hypertension—Epirubicin—liver cancer	0.000312	0.000797	CcSEcCtD
Pergolide—Ill-defined disorder—Doxorubicin—liver cancer	0.00031	0.000793	CcSEcCtD
Pergolide—Anaemia—Doxorubicin—liver cancer	0.000309	0.00079	CcSEcCtD
Pergolide—Arthralgia—Epirubicin—liver cancer	0.000307	0.000786	CcSEcCtD
Pergolide—Myalgia—Epirubicin—liver cancer	0.000307	0.000786	CcSEcCtD
Pergolide—Chest pain—Epirubicin—liver cancer	0.000307	0.000786	CcSEcCtD
Pergolide—Agitation—Doxorubicin—liver cancer	0.000307	0.000785	CcSEcCtD
Pergolide—Anxiety—Epirubicin—liver cancer	0.000306	0.000784	CcSEcCtD
Pergolide—Discomfort—Epirubicin—liver cancer	0.000304	0.000777	CcSEcCtD
Pergolide—Malaise—Doxorubicin—liver cancer	0.000301	0.000771	CcSEcCtD
Pergolide—Dry mouth—Epirubicin—liver cancer	0.000301	0.000769	CcSEcCtD
Pergolide—Vertigo—Doxorubicin—liver cancer	0.0003	0.000768	CcSEcCtD
Pergolide—Syncope—Doxorubicin—liver cancer	0.0003	0.000766	CcSEcCtD
Pergolide—Leukopenia—Doxorubicin—liver cancer	0.000299	0.000765	CcSEcCtD
Pergolide—Confusional state—Epirubicin—liver cancer	0.000297	0.00076	CcSEcCtD
Pergolide—Palpitations—Doxorubicin—liver cancer	0.000295	0.000755	CcSEcCtD
Pergolide—Oedema—Epirubicin—liver cancer	0.000295	0.000754	CcSEcCtD
Pergolide—Loss of consciousness—Doxorubicin—liver cancer	0.000294	0.000751	CcSEcCtD
Pergolide—Infection—Epirubicin—liver cancer	0.000293	0.000749	CcSEcCtD
Pergolide—Cough—Doxorubicin—liver cancer	0.000292	0.000746	CcSEcCtD
Pergolide—Shock—Epirubicin—liver cancer	0.00029	0.000742	CcSEcCtD
Pergolide—Convulsion—Doxorubicin—liver cancer	0.000289	0.000741	CcSEcCtD
Pergolide—Thrombocytopenia—Epirubicin—liver cancer	0.000289	0.000738	CcSEcCtD
Pergolide—Hypertension—Doxorubicin—liver cancer	0.000288	0.000738	CcSEcCtD
Pergolide—Tachycardia—Epirubicin—liver cancer	0.000288	0.000736	CcSEcCtD
Pergolide—Hyperhidrosis—Epirubicin—liver cancer	0.000285	0.000729	CcSEcCtD
Pergolide—Myalgia—Doxorubicin—liver cancer	0.000284	0.000728	CcSEcCtD
Pergolide—Chest pain—Doxorubicin—liver cancer	0.000284	0.000728	CcSEcCtD
Pergolide—Arthralgia—Doxorubicin—liver cancer	0.000284	0.000728	CcSEcCtD
Pergolide—Anxiety—Doxorubicin—liver cancer	0.000283	0.000725	CcSEcCtD
Pergolide—Discomfort—Doxorubicin—liver cancer	0.000281	0.000719	CcSEcCtD
Pergolide—Anorexia—Epirubicin—liver cancer	0.000281	0.000719	CcSEcCtD
Pergolide—Dry mouth—Doxorubicin—liver cancer	0.000278	0.000712	CcSEcCtD
Pergolide—Hypotension—Epirubicin—liver cancer	0.000275	0.000704	CcSEcCtD
Pergolide—Confusional state—Doxorubicin—liver cancer	0.000275	0.000703	CcSEcCtD
Pergolide—Oedema—Doxorubicin—liver cancer	0.000273	0.000698	CcSEcCtD
Pergolide—Infection—Doxorubicin—liver cancer	0.000271	0.000693	CcSEcCtD
Pergolide—Musculoskeletal discomfort—Epirubicin—liver cancer	0.000269	0.000687	CcSEcCtD
Pergolide—Shock—Doxorubicin—liver cancer	0.000268	0.000686	CcSEcCtD
Pergolide—Thrombocytopenia—Doxorubicin—liver cancer	0.000267	0.000683	CcSEcCtD
Pergolide—Insomnia—Epirubicin—liver cancer	0.000267	0.000682	CcSEcCtD
Pergolide—Tachycardia—Doxorubicin—liver cancer	0.000266	0.000681	CcSEcCtD
Pergolide—Paraesthesia—Epirubicin—liver cancer	0.000265	0.000677	CcSEcCtD
Pergolide—Hyperhidrosis—Doxorubicin—liver cancer	0.000264	0.000674	CcSEcCtD
Pergolide—Dyspnoea—Epirubicin—liver cancer	0.000263	0.000672	CcSEcCtD
Pergolide—Somnolence—Epirubicin—liver cancer	0.000262	0.00067	CcSEcCtD
Pergolide—Anorexia—Doxorubicin—liver cancer	0.00026	0.000665	CcSEcCtD
Pergolide—Dyspepsia—Epirubicin—liver cancer	0.000259	0.000664	CcSEcCtD
Pergolide—Decreased appetite—Epirubicin—liver cancer	0.000256	0.000655	CcSEcCtD
Pergolide—Hypotension—Doxorubicin—liver cancer	0.000255	0.000652	CcSEcCtD
Pergolide—Pain—Epirubicin—liver cancer	0.000252	0.000645	CcSEcCtD
Pergolide—Constipation—Epirubicin—liver cancer	0.000252	0.000645	CcSEcCtD
Pergolide—Musculoskeletal discomfort—Doxorubicin—liver cancer	0.000248	0.000636	CcSEcCtD
Pergolide—Insomnia—Doxorubicin—liver cancer	0.000247	0.000631	CcSEcCtD
Pergolide—Paraesthesia—Doxorubicin—liver cancer	0.000245	0.000626	CcSEcCtD
Pergolide—Dyspnoea—Doxorubicin—liver cancer	0.000243	0.000622	CcSEcCtD
Pergolide—Feeling abnormal—Epirubicin—liver cancer	0.000243	0.000621	CcSEcCtD
Pergolide—Somnolence—Doxorubicin—liver cancer	0.000242	0.00062	CcSEcCtD
Pergolide—Gastrointestinal pain—Epirubicin—liver cancer	0.000241	0.000616	CcSEcCtD
Pergolide—Dyspepsia—Doxorubicin—liver cancer	0.00024	0.000614	CcSEcCtD
Pergolide—Decreased appetite—Doxorubicin—liver cancer	0.000237	0.000606	CcSEcCtD
Pergolide—Constipation—Doxorubicin—liver cancer	0.000233	0.000596	CcSEcCtD
Pergolide—Pain—Doxorubicin—liver cancer	0.000233	0.000596	CcSEcCtD
Pergolide—Body temperature increased—Epirubicin—liver cancer	0.000233	0.000596	CcSEcCtD
Pergolide—Abdominal pain—Epirubicin—liver cancer	0.000233	0.000596	CcSEcCtD
Pergolide—Feeling abnormal—Doxorubicin—liver cancer	0.000225	0.000575	CcSEcCtD
Pergolide—Gastrointestinal pain—Doxorubicin—liver cancer	0.000223	0.00057	CcSEcCtD
Pergolide—Abdominal pain—Doxorubicin—liver cancer	0.000216	0.000551	CcSEcCtD
Pergolide—Body temperature increased—Doxorubicin—liver cancer	0.000216	0.000551	CcSEcCtD
Pergolide—Asthenia—Epirubicin—liver cancer	0.000211	0.000541	CcSEcCtD
Pergolide—Pruritus—Epirubicin—liver cancer	0.000209	0.000533	CcSEcCtD
Pergolide—Diarrhoea—Epirubicin—liver cancer	0.000202	0.000516	CcSEcCtD
Pergolide—Asthenia—Doxorubicin—liver cancer	0.000196	0.0005	CcSEcCtD
Pergolide—Dizziness—Epirubicin—liver cancer	0.000195	0.000499	CcSEcCtD
Pergolide—Pruritus—Doxorubicin—liver cancer	0.000193	0.000493	CcSEcCtD
Pergolide—Vomiting—Epirubicin—liver cancer	0.000187	0.000479	CcSEcCtD
Pergolide—Diarrhoea—Doxorubicin—liver cancer	0.000187	0.000477	CcSEcCtD
Pergolide—Rash—Epirubicin—liver cancer	0.000186	0.000475	CcSEcCtD
Pergolide—Dermatitis—Epirubicin—liver cancer	0.000186	0.000475	CcSEcCtD
Pergolide—Headache—Epirubicin—liver cancer	0.000185	0.000472	CcSEcCtD
Pergolide—Dizziness—Doxorubicin—liver cancer	0.00018	0.000461	CcSEcCtD
Pergolide—Nausea—Epirubicin—liver cancer	0.000175	0.000448	CcSEcCtD
Pergolide—Vomiting—Doxorubicin—liver cancer	0.000173	0.000443	CcSEcCtD
Pergolide—Rash—Doxorubicin—liver cancer	0.000172	0.00044	CcSEcCtD
Pergolide—Dermatitis—Doxorubicin—liver cancer	0.000172	0.000439	CcSEcCtD
Pergolide—Headache—Doxorubicin—liver cancer	0.000171	0.000437	CcSEcCtD
Pergolide—Nausea—Doxorubicin—liver cancer	0.000162	0.000414	CcSEcCtD
Pergolide—ADRA1A—Signaling by GPCR—PIK3CA—liver cancer	8.72e-06	8.54e-05	CbGpPWpGaD
Pergolide—DRD5—Signaling Pathways—AKT1—liver cancer	8.71e-06	8.53e-05	CbGpPWpGaD
Pergolide—HTR1B—Signaling Pathways—KRAS—liver cancer	8.7e-06	8.53e-05	CbGpPWpGaD
Pergolide—ADRA1B—Signaling by GPCR—IL6—liver cancer	8.69e-06	8.52e-05	CbGpPWpGaD
Pergolide—HTR1A—Signaling Pathways—MMP9—liver cancer	8.68e-06	8.51e-05	CbGpPWpGaD
Pergolide—CYP3A4—Metabolism—CYCS—liver cancer	8.68e-06	8.51e-05	CbGpPWpGaD
Pergolide—ADRA1A—Signaling Pathways—RAF1—liver cancer	8.66e-06	8.48e-05	CbGpPWpGaD
Pergolide—ADRA2C—Signaling Pathways—CCND1—liver cancer	8.65e-06	8.48e-05	CbGpPWpGaD
Pergolide—HTR1A—Signaling Pathways—CDKN1A—liver cancer	8.65e-06	8.48e-05	CbGpPWpGaD
Pergolide—HTR2C—Signaling Pathways—MMP9—liver cancer	8.64e-06	8.46e-05	CbGpPWpGaD
Pergolide—ADRA2C—Signaling Pathways—JUN—liver cancer	8.64e-06	8.46e-05	CbGpPWpGaD
Pergolide—HTR2A—Signaling Pathways—MTOR—liver cancer	8.63e-06	8.46e-05	CbGpPWpGaD
Pergolide—HTR2A—Signaling Pathways—PIK3CB—liver cancer	8.63e-06	8.46e-05	CbGpPWpGaD
Pergolide—HTR2C—Signaling Pathways—CDKN1A—liver cancer	8.61e-06	8.43e-05	CbGpPWpGaD
Pergolide—ADRA2C—Signaling Pathways—CTNNB1—liver cancer	8.57e-06	8.4e-05	CbGpPWpGaD
Pergolide—DRD4—Signaling Pathways—KRAS—liver cancer	8.56e-06	8.39e-05	CbGpPWpGaD
Pergolide—CYP3A4—Metabolism—GOT1—liver cancer	8.52e-06	8.35e-05	CbGpPWpGaD
Pergolide—CYP3A4—Metabolism—GGT1—liver cancer	8.52e-06	8.35e-05	CbGpPWpGaD
Pergolide—ADRA1B—Signaling Pathways—CCND1—liver cancer	8.52e-06	8.35e-05	CbGpPWpGaD
Pergolide—ADRA1B—Signaling Pathways—JUN—liver cancer	8.5e-06	8.33e-05	CbGpPWpGaD
Pergolide—ADRA1A—Signaling Pathways—MTOR—liver cancer	8.45e-06	8.28e-05	CbGpPWpGaD
Pergolide—ADRA1A—Signaling Pathways—PIK3CB—liver cancer	8.45e-06	8.28e-05	CbGpPWpGaD
Pergolide—HTR1A—Signaling Pathways—MAPK8—liver cancer	8.44e-06	8.27e-05	CbGpPWpGaD
Pergolide—ADRA1B—Signaling Pathways—CTNNB1—liver cancer	8.43e-06	8.26e-05	CbGpPWpGaD
Pergolide—HTR1A—Signaling by GPCR—AKT1—liver cancer	8.42e-06	8.25e-05	CbGpPWpGaD
Pergolide—ADRA2C—Signaling Pathways—MMP9—liver cancer	8.4e-06	8.23e-05	CbGpPWpGaD
Pergolide—HTR2C—Signaling Pathways—MAPK8—liver cancer	8.4e-06	8.23e-05	CbGpPWpGaD
Pergolide—HTR2C—Signaling by GPCR—AKT1—liver cancer	8.38e-06	8.21e-05	CbGpPWpGaD
Pergolide—DRD2—Signaling by GPCR—HRAS—liver cancer	8.37e-06	8.21e-05	CbGpPWpGaD
Pergolide—ADRA2C—Signaling Pathways—CDKN1A—liver cancer	8.37e-06	8.2e-05	CbGpPWpGaD
Pergolide—DRD1—Signaling Pathways—MYC—liver cancer	8.34e-06	8.17e-05	CbGpPWpGaD
Pergolide—DRD1—Signaling Pathways—TGFB1—liver cancer	8.32e-06	8.15e-05	CbGpPWpGaD
Pergolide—ADRA1B—Signaling Pathways—MMP9—liver cancer	8.27e-06	8.1e-05	CbGpPWpGaD
Pergolide—HTR2A—Signaling by GPCR—HRAS—liver cancer	8.24e-06	8.07e-05	CbGpPWpGaD
Pergolide—ADRA1B—Signaling Pathways—CDKN1A—liver cancer	8.24e-06	8.07e-05	CbGpPWpGaD
Pergolide—DRD2—Signaling Pathways—CDKN1B—liver cancer	8.23e-06	8.07e-05	CbGpPWpGaD
Pergolide—DRD3—Signaling Pathways—MYC—liver cancer	8.23e-06	8.07e-05	CbGpPWpGaD
Pergolide—ADRA1D—Signaling Pathways—MYC—liver cancer	8.23e-06	8.07e-05	CbGpPWpGaD
Pergolide—ADRA1D—Signaling Pathways—TGFB1—liver cancer	8.21e-06	8.05e-05	CbGpPWpGaD
Pergolide—DRD3—Signaling Pathways—TGFB1—liver cancer	8.21e-06	8.05e-05	CbGpPWpGaD
Pergolide—HTR2B—Signaling Pathways—KRAS—liver cancer	8.17e-06	8.01e-05	CbGpPWpGaD
Pergolide—ADRA2C—Signaling Pathways—MAPK8—liver cancer	8.17e-06	8.01e-05	CbGpPWpGaD
Pergolide—HTR1D—Signaling Pathways—PIK3CA—liver cancer	8.16e-06	8e-05	CbGpPWpGaD
Pergolide—ADRA2C—Signaling by GPCR—AKT1—liver cancer	8.15e-06	7.98e-05	CbGpPWpGaD
Pergolide—DRD2—GPCR downstream signaling—AKT1—liver cancer	8.14e-06	7.98e-05	CbGpPWpGaD
Pergolide—ADRA2A—Signaling by GPCR—PIK3CA—liver cancer	8.1e-06	7.94e-05	CbGpPWpGaD
Pergolide—HTR2A—Signaling Pathways—CDKN1B—liver cancer	8.1e-06	7.94e-05	CbGpPWpGaD
Pergolide—ADRA2B—Signaling Pathways—VEGFA—liver cancer	8.08e-06	7.91e-05	CbGpPWpGaD
Pergolide—ADRA1A—Signaling by GPCR—HRAS—liver cancer	8.07e-06	7.91e-05	CbGpPWpGaD
Pergolide—DRD2—Signaling Pathways—CASP3—liver cancer	8.07e-06	7.9e-05	CbGpPWpGaD
Pergolide—DRD2—Signaling Pathways—IL2—liver cancer	8.06e-06	7.89e-05	CbGpPWpGaD
Pergolide—ADRA1B—Signaling Pathways—MAPK8—liver cancer	8.04e-06	7.88e-05	CbGpPWpGaD
Pergolide—ADRA2A—Signaling Pathways—RAF1—liver cancer	8.04e-06	7.88e-05	CbGpPWpGaD
Pergolide—ADRA1B—Signaling by GPCR—AKT1—liver cancer	8.02e-06	7.86e-05	CbGpPWpGaD
Pergolide—DRD2—Signaling by GPCR—IL6—liver cancer	8.01e-06	7.85e-05	CbGpPWpGaD
Pergolide—HTR2A—GPCR downstream signaling—AKT1—liver cancer	8.01e-06	7.85e-05	CbGpPWpGaD
Pergolide—ADRA2B—Signaling Pathways—STAT3—liver cancer	8e-06	7.84e-05	CbGpPWpGaD
Pergolide—HTR1B—Signaling Pathways—PIK3CA—liver cancer	7.99e-06	7.83e-05	CbGpPWpGaD
Pergolide—CYP2D6—Metabolism—PIK3CG—liver cancer	7.99e-06	7.82e-05	CbGpPWpGaD
Pergolide—HTR2A—Signaling Pathways—CASP3—liver cancer	7.94e-06	7.78e-05	CbGpPWpGaD
Pergolide—ADRA1A—Signaling Pathways—CDKN1B—liver cancer	7.93e-06	7.77e-05	CbGpPWpGaD
Pergolide—HTR2A—Signaling Pathways—IL2—liver cancer	7.93e-06	7.77e-05	CbGpPWpGaD
Pergolide—HTR1D—Signaling Pathways—TP53—liver cancer	7.9e-06	7.74e-05	CbGpPWpGaD
Pergolide—HTR2A—Signaling by GPCR—IL6—liver cancer	7.89e-06	7.73e-05	CbGpPWpGaD
Pergolide—DRD4—Signaling Pathways—PIK3CA—liver cancer	7.87e-06	7.71e-05	CbGpPWpGaD
Pergolide—DRD2—Signaling Pathways—CCND1—liver cancer	7.85e-06	7.69e-05	CbGpPWpGaD
Pergolide—ADRA2A—Signaling Pathways—PIK3CB—liver cancer	7.85e-06	7.69e-05	CbGpPWpGaD
Pergolide—ADRA2A—Signaling Pathways—MTOR—liver cancer	7.85e-06	7.69e-05	CbGpPWpGaD
Pergolide—ADRA1A—GPCR downstream signaling—AKT1—liver cancer	7.84e-06	7.69e-05	CbGpPWpGaD
Pergolide—DRD2—Signaling Pathways—JUN—liver cancer	7.84e-06	7.68e-05	CbGpPWpGaD
Pergolide—HTR1A—Signaling Pathways—VEGFA—liver cancer	7.8e-06	7.64e-05	CbGpPWpGaD
Pergolide—DRD2—Signaling Pathways—CTNNB1—liver cancer	7.78e-06	7.62e-05	CbGpPWpGaD
Pergolide—ADRA1A—Signaling Pathways—CASP3—liver cancer	7.77e-06	7.62e-05	CbGpPWpGaD
Pergolide—ADRA1A—Signaling Pathways—IL2—liver cancer	7.76e-06	7.6e-05	CbGpPWpGaD
Pergolide—HTR2C—Signaling Pathways—VEGFA—liver cancer	7.76e-06	7.6e-05	CbGpPWpGaD
Pergolide—HTR1B—Signaling Pathways—TP53—liver cancer	7.73e-06	7.58e-05	CbGpPWpGaD
Pergolide—HTR2A—Signaling Pathways—CCND1—liver cancer	7.73e-06	7.57e-05	CbGpPWpGaD
Pergolide—ADRA1A—Signaling by GPCR—IL6—liver cancer	7.72e-06	7.57e-05	CbGpPWpGaD
Pergolide—HTR1A—Signaling Pathways—STAT3—liver cancer	7.72e-06	7.56e-05	CbGpPWpGaD
Pergolide—HTR2A—Signaling Pathways—JUN—liver cancer	7.71e-06	7.55e-05	CbGpPWpGaD
Pergolide—DRD1—Signaling Pathways—KRAS—liver cancer	7.71e-06	7.55e-05	CbGpPWpGaD
Pergolide—CYP2D6—Metabolism—PPARG—liver cancer	7.71e-06	7.55e-05	CbGpPWpGaD
Pergolide—HTR2C—Signaling Pathways—STAT3—liver cancer	7.68e-06	7.53e-05	CbGpPWpGaD
Pergolide—HTR2A—Signaling Pathways—CTNNB1—liver cancer	7.65e-06	7.5e-05	CbGpPWpGaD
Pergolide—CYP3A4—Metabolism—GSTP1—liver cancer	7.65e-06	7.5e-05	CbGpPWpGaD
Pergolide—DRD2—Signaling Pathways—MMP9—liver cancer	7.62e-06	7.47e-05	CbGpPWpGaD
Pergolide—DRD4—Signaling Pathways—TP53—liver cancer	7.61e-06	7.46e-05	CbGpPWpGaD
Pergolide—ADRA1D—Signaling Pathways—KRAS—liver cancer	7.61e-06	7.45e-05	CbGpPWpGaD
Pergolide—DRD3—Signaling Pathways—KRAS—liver cancer	7.61e-06	7.45e-05	CbGpPWpGaD
Pergolide—DRD2—Signaling Pathways—CDKN1A—liver cancer	7.6e-06	7.44e-05	CbGpPWpGaD
Pergolide—ADRA1A—Signaling Pathways—CCND1—liver cancer	7.57e-06	7.41e-05	CbGpPWpGaD
Pergolide—HTR1D—Signaling Pathways—HRAS—liver cancer	7.55e-06	7.4e-05	CbGpPWpGaD
Pergolide—ADRA1A—Signaling Pathways—JUN—liver cancer	7.55e-06	7.4e-05	CbGpPWpGaD
Pergolide—CYP3A4—Metabolism—HMOX1—liver cancer	7.55e-06	7.39e-05	CbGpPWpGaD
Pergolide—ADRA2C—Signaling Pathways—VEGFA—liver cancer	7.54e-06	7.39e-05	CbGpPWpGaD
Pergolide—HTR2B—Signaling Pathways—PIK3CA—liver cancer	7.51e-06	7.36e-05	CbGpPWpGaD
Pergolide—HTR2A—Signaling Pathways—MMP9—liver cancer	7.5e-06	7.35e-05	CbGpPWpGaD
Pergolide—ADRA2A—Signaling by GPCR—HRAS—liver cancer	7.5e-06	7.35e-05	CbGpPWpGaD
Pergolide—ADRA1A—Signaling Pathways—CTNNB1—liver cancer	7.49e-06	7.34e-05	CbGpPWpGaD
Pergolide—HTR2A—Signaling Pathways—CDKN1A—liver cancer	7.47e-06	7.32e-05	CbGpPWpGaD
Pergolide—ADRA2C—Signaling Pathways—STAT3—liver cancer	7.47e-06	7.32e-05	CbGpPWpGaD
Pergolide—ADRA2B—Signaling Pathways—MYC—liver cancer	7.43e-06	7.28e-05	CbGpPWpGaD
Pergolide—ADRA1B—Signaling Pathways—VEGFA—liver cancer	7.43e-06	7.28e-05	CbGpPWpGaD
Pergolide—DRD2—Signaling Pathways—MAPK8—liver cancer	7.41e-06	7.26e-05	CbGpPWpGaD
Pergolide—ADRA2B—Signaling Pathways—TGFB1—liver cancer	7.41e-06	7.26e-05	CbGpPWpGaD
Pergolide—HTR1B—Signaling Pathways—HRAS—liver cancer	7.4e-06	7.25e-05	CbGpPWpGaD
Pergolide—DRD2—Signaling by GPCR—AKT1—liver cancer	7.39e-06	7.25e-05	CbGpPWpGaD
Pergolide—ADRA2A—Signaling Pathways—CDKN1B—liver cancer	7.37e-06	7.22e-05	CbGpPWpGaD
Pergolide—ADRA1B—Signaling Pathways—STAT3—liver cancer	7.35e-06	7.2e-05	CbGpPWpGaD
Pergolide—ADRA1A—Signaling Pathways—MMP9—liver cancer	7.34e-06	7.2e-05	CbGpPWpGaD
Pergolide—ADRA1A—Signaling Pathways—CDKN1A—liver cancer	7.32e-06	7.17e-05	CbGpPWpGaD
Pergolide—HTR2A—Signaling Pathways—MAPK8—liver cancer	7.3e-06	7.15e-05	CbGpPWpGaD
Pergolide—ADRA2A—GPCR downstream signaling—AKT1—liver cancer	7.29e-06	7.14e-05	CbGpPWpGaD
Pergolide—DRD4—Signaling Pathways—HRAS—liver cancer	7.28e-06	7.13e-05	CbGpPWpGaD
Pergolide—HTR2A—Signaling by GPCR—AKT1—liver cancer	7.28e-06	7.13e-05	CbGpPWpGaD
Pergolide—HTR2B—Signaling Pathways—TP53—liver cancer	7.26e-06	7.12e-05	CbGpPWpGaD
Pergolide—HTR1D—Signaling Pathways—IL6—liver cancer	7.23e-06	7.08e-05	CbGpPWpGaD
Pergolide—ADRA2A—Signaling Pathways—CASP3—liver cancer	7.22e-06	7.08e-05	CbGpPWpGaD
Pergolide—ADRA2A—Signaling Pathways—IL2—liver cancer	7.21e-06	7.07e-05	CbGpPWpGaD
Pergolide—ADRA2A—Signaling by GPCR—IL6—liver cancer	7.17e-06	7.03e-05	CbGpPWpGaD
Pergolide—HTR1A—Signaling Pathways—MYC—liver cancer	7.17e-06	7.03e-05	CbGpPWpGaD
Pergolide—HTR1A—Signaling Pathways—TGFB1—liver cancer	7.16e-06	7.01e-05	CbGpPWpGaD
Pergolide—ADRA1A—Signaling Pathways—MAPK8—liver cancer	7.14e-06	7e-05	CbGpPWpGaD
Pergolide—HTR2C—Signaling Pathways—MYC—liver cancer	7.14e-06	6.99e-05	CbGpPWpGaD
Pergolide—ADRA1A—Signaling by GPCR—AKT1—liver cancer	7.12e-06	6.98e-05	CbGpPWpGaD
Pergolide—HTR2C—Signaling Pathways—TGFB1—liver cancer	7.12e-06	6.98e-05	CbGpPWpGaD
Pergolide—DRD1—Signaling Pathways—PIK3CA—liver cancer	7.08e-06	6.94e-05	CbGpPWpGaD
Pergolide—HTR1B—Signaling Pathways—IL6—liver cancer	7.08e-06	6.94e-05	CbGpPWpGaD
Pergolide—ADRA2C—Metabolism—PIK3CA—liver cancer	7.05e-06	6.91e-05	CbGpPWpGaD
Pergolide—CYP3A4—Metabolism—GSTM1—liver cancer	7.03e-06	6.89e-05	CbGpPWpGaD
Pergolide—ADRA2A—Signaling Pathways—CCND1—liver cancer	7.03e-06	6.89e-05	CbGpPWpGaD
Pergolide—CYP2D6—Metabolism—PIK3CD—liver cancer	7.02e-06	6.88e-05	CbGpPWpGaD
Pergolide—ADRA2A—Signaling Pathways—JUN—liver cancer	7.01e-06	6.87e-05	CbGpPWpGaD
Pergolide—ADRA1D—Signaling Pathways—PIK3CA—liver cancer	6.99e-06	6.85e-05	CbGpPWpGaD
Pergolide—DRD3—Signaling Pathways—PIK3CA—liver cancer	6.99e-06	6.85e-05	CbGpPWpGaD
Pergolide—DRD4—Signaling Pathways—IL6—liver cancer	6.97e-06	6.83e-05	CbGpPWpGaD
Pergolide—ADRA2A—Signaling Pathways—CTNNB1—liver cancer	6.96e-06	6.82e-05	CbGpPWpGaD
Pergolide—HTR2B—Signaling Pathways—HRAS—liver cancer	6.95e-06	6.81e-05	CbGpPWpGaD
Pergolide—ADRA2C—Signaling Pathways—MYC—liver cancer	6.94e-06	6.8e-05	CbGpPWpGaD
Pergolide—CYP2D6—Metabolism—ALB—liver cancer	6.93e-06	6.79e-05	CbGpPWpGaD
Pergolide—ADRA2C—Signaling Pathways—TGFB1—liver cancer	6.92e-06	6.79e-05	CbGpPWpGaD
Pergolide—ADRA2B—Signaling Pathways—KRAS—liver cancer	6.87e-06	6.73e-05	CbGpPWpGaD
Pergolide—DRD1—Signaling Pathways—TP53—liver cancer	6.85e-06	6.71e-05	CbGpPWpGaD
Pergolide—DRD2—Signaling Pathways—VEGFA—liver cancer	6.85e-06	6.71e-05	CbGpPWpGaD
Pergolide—ADRA1B—Signaling Pathways—MYC—liver cancer	6.83e-06	6.69e-05	CbGpPWpGaD
Pergolide—ADRA2A—Signaling Pathways—MMP9—liver cancer	6.82e-06	6.69e-05	CbGpPWpGaD
Pergolide—ADRA1B—Signaling Pathways—TGFB1—liver cancer	6.82e-06	6.68e-05	CbGpPWpGaD
Pergolide—ADRA2A—Signaling Pathways—CDKN1A—liver cancer	6.8e-06	6.66e-05	CbGpPWpGaD
Pergolide—DRD2—Signaling Pathways—STAT3—liver cancer	6.78e-06	6.64e-05	CbGpPWpGaD
Pergolide—ADRA1D—Signaling Pathways—TP53—liver cancer	6.76e-06	6.62e-05	CbGpPWpGaD
Pergolide—DRD3—Signaling Pathways—TP53—liver cancer	6.76e-06	6.62e-05	CbGpPWpGaD
Pergolide—HTR2A—Signaling Pathways—VEGFA—liver cancer	6.74e-06	6.6e-05	CbGpPWpGaD
Pergolide—HTR1D—Signaling Pathways—AKT1—liver cancer	6.67e-06	6.54e-05	CbGpPWpGaD
Pergolide—HTR2A—Signaling Pathways—STAT3—liver cancer	6.67e-06	6.54e-05	CbGpPWpGaD
Pergolide—CYP3A4—Metabolism—CYP1A1—liver cancer	6.67e-06	6.53e-05	CbGpPWpGaD
Pergolide—HTR2B—Signaling Pathways—IL6—liver cancer	6.65e-06	6.52e-05	CbGpPWpGaD
Pergolide—ADRA2A—Signaling Pathways—MAPK8—liver cancer	6.64e-06	6.5e-05	CbGpPWpGaD
Pergolide—HTR1A—Signaling Pathways—KRAS—liver cancer	6.63e-06	6.49e-05	CbGpPWpGaD
Pergolide—ADRA2A—Signaling by GPCR—AKT1—liver cancer	6.62e-06	6.49e-05	CbGpPWpGaD
Pergolide—ADRA1A—Signaling Pathways—VEGFA—liver cancer	6.6e-06	6.46e-05	CbGpPWpGaD
Pergolide—HTR2C—Signaling Pathways—KRAS—liver cancer	6.59e-06	6.46e-05	CbGpPWpGaD
Pergolide—DRD1—Signaling Pathways—HRAS—liver cancer	6.55e-06	6.42e-05	CbGpPWpGaD
Pergolide—HTR1B—Signaling Pathways—AKT1—liver cancer	6.53e-06	6.4e-05	CbGpPWpGaD
Pergolide—ADRA1A—Signaling Pathways—STAT3—liver cancer	6.53e-06	6.4e-05	CbGpPWpGaD
Pergolide—ADRA1D—Signaling Pathways—HRAS—liver cancer	6.46e-06	6.33e-05	CbGpPWpGaD
Pergolide—DRD3—Signaling Pathways—HRAS—liver cancer	6.46e-06	6.33e-05	CbGpPWpGaD
Pergolide—DRD4—Signaling Pathways—AKT1—liver cancer	6.43e-06	6.3e-05	CbGpPWpGaD
Pergolide—ADRA2C—Signaling Pathways—KRAS—liver cancer	6.41e-06	6.28e-05	CbGpPWpGaD
Pergolide—ADRA1B—Signaling Pathways—KRAS—liver cancer	6.31e-06	6.19e-05	CbGpPWpGaD
Pergolide—ADRA2B—Signaling Pathways—PIK3CA—liver cancer	6.31e-06	6.18e-05	CbGpPWpGaD
Pergolide—DRD2—Signaling Pathways—MYC—liver cancer	6.3e-06	6.17e-05	CbGpPWpGaD
Pergolide—DRD2—Signaling Pathways—TGFB1—liver cancer	6.28e-06	6.16e-05	CbGpPWpGaD
Pergolide—DRD1—Signaling Pathways—IL6—liver cancer	6.27e-06	6.14e-05	CbGpPWpGaD
Pergolide—CYP3A4—Metabolism—MTHFR—liver cancer	6.21e-06	6.09e-05	CbGpPWpGaD
Pergolide—HTR2A—Signaling Pathways—MYC—liver cancer	6.2e-06	6.07e-05	CbGpPWpGaD
Pergolide—DRD3—Signaling Pathways—IL6—liver cancer	6.19e-06	6.06e-05	CbGpPWpGaD
Pergolide—ADRA1D—Signaling Pathways—IL6—liver cancer	6.19e-06	6.06e-05	CbGpPWpGaD
Pergolide—HTR2A—Signaling Pathways—TGFB1—liver cancer	6.18e-06	6.06e-05	CbGpPWpGaD
Pergolide—HTR2B—Signaling Pathways—AKT1—liver cancer	6.13e-06	6.01e-05	CbGpPWpGaD
Pergolide—ADRA2A—Signaling Pathways—VEGFA—liver cancer	6.13e-06	6e-05	CbGpPWpGaD
Pergolide—CYP2D6—Metabolism—PIK3CB—liver cancer	6.12e-06	6e-05	CbGpPWpGaD
Pergolide—ADRA2B—Signaling Pathways—TP53—liver cancer	6.1e-06	5.98e-05	CbGpPWpGaD
Pergolide—CYP3A4—Metabolism—PPARA—liver cancer	6.1e-06	5.97e-05	CbGpPWpGaD
Pergolide—HTR1A—Signaling Pathways—PIK3CA—liver cancer	6.09e-06	5.97e-05	CbGpPWpGaD
Pergolide—ADRA1A—Signaling Pathways—MYC—liver cancer	6.07e-06	5.95e-05	CbGpPWpGaD
Pergolide—ADRA2A—Signaling Pathways—STAT3—liver cancer	6.07e-06	5.95e-05	CbGpPWpGaD
Pergolide—HTR2C—Signaling Pathways—PIK3CA—liver cancer	6.06e-06	5.94e-05	CbGpPWpGaD
Pergolide—ADRA1A—Signaling Pathways—TGFB1—liver cancer	6.05e-06	5.93e-05	CbGpPWpGaD
Pergolide—ADRA2C—Signaling Pathways—PIK3CA—liver cancer	5.89e-06	5.77e-05	CbGpPWpGaD
Pergolide—HTR1A—Signaling Pathways—TP53—liver cancer	5.89e-06	5.77e-05	CbGpPWpGaD
Pergolide—HTR2C—Signaling Pathways—TP53—liver cancer	5.86e-06	5.74e-05	CbGpPWpGaD
Pergolide—ADRA2B—Signaling Pathways—HRAS—liver cancer	5.84e-06	5.72e-05	CbGpPWpGaD
Pergolide—DRD2—Signaling Pathways—KRAS—liver cancer	5.82e-06	5.7e-05	CbGpPWpGaD
Pergolide—ADRA1B—Signaling Pathways—PIK3CA—liver cancer	5.8e-06	5.68e-05	CbGpPWpGaD
Pergolide—DRD1—Signaling Pathways—AKT1—liver cancer	5.79e-06	5.67e-05	CbGpPWpGaD
Pergolide—ADRA2C—Metabolism—AKT1—liver cancer	5.76e-06	5.64e-05	CbGpPWpGaD
Pergolide—HTR2A—Signaling Pathways—KRAS—liver cancer	5.73e-06	5.61e-05	CbGpPWpGaD
Pergolide—ADRA2A—Metabolism—PIK3CA—liver cancer	5.72e-06	5.61e-05	CbGpPWpGaD
Pergolide—ADRA1D—Signaling Pathways—AKT1—liver cancer	5.71e-06	5.59e-05	CbGpPWpGaD
Pergolide—DRD3—Signaling Pathways—AKT1—liver cancer	5.71e-06	5.59e-05	CbGpPWpGaD
Pergolide—ADRA2C—Signaling Pathways—TP53—liver cancer	5.7e-06	5.59e-05	CbGpPWpGaD
Pergolide—ADRA2A—Signaling Pathways—MYC—liver cancer	5.64e-06	5.52e-05	CbGpPWpGaD
Pergolide—HTR1A—Signaling Pathways—HRAS—liver cancer	5.63e-06	5.52e-05	CbGpPWpGaD
Pergolide—ADRA2A—Signaling Pathways—TGFB1—liver cancer	5.62e-06	5.51e-05	CbGpPWpGaD
Pergolide—ADRA1B—Signaling Pathways—TP53—liver cancer	5.61e-06	5.5e-05	CbGpPWpGaD
Pergolide—ADRA1A—Signaling Pathways—KRAS—liver cancer	5.61e-06	5.49e-05	CbGpPWpGaD
Pergolide—HTR2C—Signaling Pathways—HRAS—liver cancer	5.61e-06	5.49e-05	CbGpPWpGaD
Pergolide—ADRA2B—Signaling Pathways—IL6—liver cancer	5.59e-06	5.47e-05	CbGpPWpGaD
Pergolide—ADRA2C—Signaling Pathways—HRAS—liver cancer	5.45e-06	5.34e-05	CbGpPWpGaD
Pergolide—HTR1A—Signaling Pathways—IL6—liver cancer	5.39e-06	5.28e-05	CbGpPWpGaD
Pergolide—ADRA1B—Signaling Pathways—HRAS—liver cancer	5.37e-06	5.26e-05	CbGpPWpGaD
Pergolide—HTR2C—Signaling Pathways—IL6—liver cancer	5.36e-06	5.26e-05	CbGpPWpGaD
Pergolide—DRD2—Signaling Pathways—PIK3CA—liver cancer	5.35e-06	5.24e-05	CbGpPWpGaD
Pergolide—HTR2A—Signaling Pathways—PIK3CA—liver cancer	5.26e-06	5.16e-05	CbGpPWpGaD
Pergolide—CYP3A4—Metabolism—PIK3CG—liver cancer	5.22e-06	5.12e-05	CbGpPWpGaD
Pergolide—ADRA2C—Signaling Pathways—IL6—liver cancer	5.22e-06	5.11e-05	CbGpPWpGaD
Pergolide—ADRA2A—Signaling Pathways—KRAS—liver cancer	5.21e-06	5.1e-05	CbGpPWpGaD
Pergolide—DRD2—Signaling Pathways—TP53—liver cancer	5.17e-06	5.07e-05	CbGpPWpGaD
Pergolide—ADRA2B—Signaling Pathways—AKT1—liver cancer	5.15e-06	5.05e-05	CbGpPWpGaD
Pergolide—ADRA1A—Signaling Pathways—PIK3CA—liver cancer	5.15e-06	5.05e-05	CbGpPWpGaD
Pergolide—ADRA1B—Signaling Pathways—IL6—liver cancer	5.14e-06	5.03e-05	CbGpPWpGaD
Pergolide—HTR2A—Signaling Pathways—TP53—liver cancer	5.09e-06	4.99e-05	CbGpPWpGaD
Pergolide—CYP3A4—Metabolism—PPARG—liver cancer	5.04e-06	4.94e-05	CbGpPWpGaD
Pergolide—ADRA1A—Signaling Pathways—TP53—liver cancer	4.98e-06	4.88e-05	CbGpPWpGaD
Pergolide—HTR1A—Signaling Pathways—AKT1—liver cancer	4.97e-06	4.87e-05	CbGpPWpGaD
Pergolide—HTR2C—Signaling Pathways—AKT1—liver cancer	4.95e-06	4.85e-05	CbGpPWpGaD
Pergolide—DRD2—Signaling Pathways—HRAS—liver cancer	4.95e-06	4.85e-05	CbGpPWpGaD
Pergolide—HTR2A—Signaling Pathways—HRAS—liver cancer	4.87e-06	4.77e-05	CbGpPWpGaD
Pergolide—ADRA2C—Signaling Pathways—AKT1—liver cancer	4.81e-06	4.72e-05	CbGpPWpGaD
Pergolide—ADRA2A—Signaling Pathways—PIK3CA—liver cancer	4.79e-06	4.69e-05	CbGpPWpGaD
Pergolide—ADRA1A—Signaling Pathways—HRAS—liver cancer	4.77e-06	4.67e-05	CbGpPWpGaD
Pergolide—ADRA1B—Signaling Pathways—AKT1—liver cancer	4.74e-06	4.64e-05	CbGpPWpGaD
Pergolide—DRD2—Signaling Pathways—IL6—liver cancer	4.73e-06	4.64e-05	CbGpPWpGaD
Pergolide—ADRA2A—Metabolism—AKT1—liver cancer	4.68e-06	4.58e-05	CbGpPWpGaD
Pergolide—HTR2A—Signaling Pathways—IL6—liver cancer	4.66e-06	4.56e-05	CbGpPWpGaD
Pergolide—ADRA2A—Signaling Pathways—TP53—liver cancer	4.63e-06	4.54e-05	CbGpPWpGaD
Pergolide—CYP3A4—Metabolism—PIK3CD—liver cancer	4.59e-06	4.5e-05	CbGpPWpGaD
Pergolide—ADRA1A—Signaling Pathways—IL6—liver cancer	4.56e-06	4.47e-05	CbGpPWpGaD
Pergolide—CYP3A4—Metabolism—ALB—liver cancer	4.53e-06	4.44e-05	CbGpPWpGaD
Pergolide—ADRA2A—Signaling Pathways—HRAS—liver cancer	4.43e-06	4.34e-05	CbGpPWpGaD
Pergolide—DRD2—Signaling Pathways—AKT1—liver cancer	4.37e-06	4.28e-05	CbGpPWpGaD
Pergolide—HTR2A—Signaling Pathways—AKT1—liver cancer	4.3e-06	4.21e-05	CbGpPWpGaD
Pergolide—ADRA2A—Signaling Pathways—IL6—liver cancer	4.24e-06	4.15e-05	CbGpPWpGaD
Pergolide—ADRA1A—Signaling Pathways—AKT1—liver cancer	4.21e-06	4.12e-05	CbGpPWpGaD
Pergolide—CYP3A4—Metabolism—PIK3CB—liver cancer	4e-06	3.92e-05	CbGpPWpGaD
Pergolide—ADRA2A—Signaling Pathways—AKT1—liver cancer	3.91e-06	3.83e-05	CbGpPWpGaD
Pergolide—CYP2D6—Metabolism—PIK3CA—liver cancer	3.73e-06	3.65e-05	CbGpPWpGaD
Pergolide—CYP2D6—Metabolism—AKT1—liver cancer	3.05e-06	2.99e-05	CbGpPWpGaD
Pergolide—CYP3A4—Metabolism—PIK3CA—liver cancer	2.44e-06	2.39e-05	CbGpPWpGaD
Pergolide—CYP3A4—Metabolism—AKT1—liver cancer	1.99e-06	1.95e-05	CbGpPWpGaD
